Summary of Significant Accounting Policies and Select Balance Sheet Information - Additional Information (Detail) - USD ($) shares in Millions	3 Months Ended							12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2010	Sep. 30, 2006	Nov. 10, 2015
Summary Of Significant Accounting Policies [Line Items]
Available for sale investments	$ 0		$ 19,863,000					$ 0	$ 19,863,000
Depreciation expense								2,000,000	2,000,000	$ 2,100,000
Gain on sale of investment		$ 500,000		$ 700,000				492,000	842,000	1,430,000
Transfer to Investments								2,000
Revenue recognized from activity with companies in which it had strategic investment										100,000
Amortization expense								800,000	700,000	700,000
Goodwill	8,010,000		8,010,000					8,010,000	8,010,000
Taxes collected from customers and remitted to governmental authorities								100,000	100,000	$ 100,000
Deferred revenue	300,000		300,000					$ 300,000	$ 300,000
Weighted average diluted shares outstanding excluded outstanding stock options								0.5	0.5	0.4
Medtronic [Member] | Customer Concentration Risk [Member] | Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Major customer percentage of consolidated revenue								26.00%	19.00%	19.00%
In Vitro Diagnostics [Member]
Summary Of Significant Accounting Policies [Line Items]
Goodwill	8,000,000		8,000,000					$ 8,000,000	$ 8,000,000
Goodwill, impairment charges								0	0	$ 0
Customer Lists [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, acquired								300,000
Non-compete [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, acquired								200,000
Other Intangible Assets [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, acquired								100,000
Nexeon Med Systems Inc
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment					$ 1,000,000			6,500,000			$ 4,100,000
Carrying value of the investment	0		0					0	0
Other Income, Net [Member]
Summary Of Significant Accounting Policies [Line Items]
Gain on sale of investment								500,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized from activity with companies in which it had strategic investment								$ 100,000	100,000
Product sales payment terms								45 days
Maximum [Member] | Customer Concentration Risk [Member] | Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Major customer percentage of consolidated revenue								10.00%
Maximum [Member] | Medtronic [Member] | Product Concentration Risk [Member] | Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Major customer percentage of consolidated revenue								6.00%
Maximum [Member] | Nexeon Med Systems Inc
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment										$ 100,000
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales payment terms								30 days
CeloNova BioSciences, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment	$ 1,500,000							$ 1,500,000
CeloNova BioSciences, Inc. [Member] | Subsequent Event [Member]
Summary Of Significant Accounting Policies [Line Items]
Gross value of business acquired													$ 70,000,000
CeloNova BioSciences, Inc. [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Company's ownership percentage	2.00%							2.00%
ThermopeutiX, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment			$ 1,200,000					$ 1,200,000
ThermopeutiX, Inc. [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Company's ownership percentage	20.00%							20.00%
ViaCyte, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment						$ 100,000		$ 5,300,000				$ 4,700,000
Cost method of investment	$ 500,000							$ 500,000
ViaCyte, Inc. [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Company's ownership percentage	1.00%							1.00%
Vessix Vascular, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment								$ 2,500,000			$ 2,400,000
Gain on sale of investment							$ 1,200,000
Vessix Vascular, Inc. [Member] | Clinical milestone [Member]
Summary Of Significant Accounting Policies [Line Items]
Milestone payment to be received									$ 700,000
Vessix Vascular, Inc. [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Potential proceeds on achievement of future milestones	$ 3,300,000							$ 3,300,000